# Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Newly Diagnosed, Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

> clinical trial · VERIFIED · 2026-06-11

Status: SUSPENDED · Sponsor: National Cancer Institute (NCI) · Condition: Desmoplastic Small Round Cell Tumor

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT04616560

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.